Skip to content
lifestyle.theroguemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
argenx SE
argenx to Present at Upcoming Investor Conferences
May 27, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 24, 2026
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 23, 2026
argenx to Present at BofA Securities 2026 Health Care Conference
May 23, 2026
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
May 23, 2026
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
May 22, 2026
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
April 18, 2026
argenx announces Annual General Meeting of Shareholders on May 6, 2026
March 20, 2026
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
March 6, 2026
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026
1
2
Next Page
→